NASDAQ:NVCRNovocure Stock Price, Forecast & News

Novocure's stock was trading at $67.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NVCR shares have increased by 10.6% and is now trading at $74.54.
View which stocks have been most impacted by COVID-19.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Novocure.

Novocure is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Novocure.

Novocure Ltd (NASDAQ:NVCR) released its earnings results on Thursday, July, 30th. The medical equipment provider reported $0.02 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.01 by $0.01. The medical equipment provider had revenue of $115.90 million for the quarter, compared to analyst estimates of $105.96 million. Novocure had a net margin of 2.88% and a return on equity of 5.14%. The company's revenue was up 33.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.01) earnings per share.
View Novocure's earnings history.

8 brokerages have issued 1-year price targets for Novocure's stock. Their forecasts range from $58.00 to $90.00. On average, they anticipate Novocure's share price to reach $79.75 in the next twelve months. This suggests a possible upside of 7.0% from the stock's current price.
View analysts' price targets for Novocure.

Media stories about NVCR stock have trended extremely negative on Wednesday, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novocure earned a news impact score of -4.1 on InfoTrie's scale. They also assigned news headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term.
View the latest news about Novocure.

Novocure saw a decrease in short interest in July. As of July 31st, there was short interest totaling 3,150,000 shares, a decrease of 6.8% from the July 15th total of 3,380,000 shares. Based on an average trading volume of 1,010,000 shares, the days-to-cover ratio is presently 3.1 days. Approximately 3.8% of the shares of the stock are short sold.
View Novocure's Short Interest.

Some companies that are related to Novocure include FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), ABIOMED (ABMD), Insulet (PODD), Penumbra (PEN), Hill-Rom (HRC), Tandem Diabetes Care (TNDM), Globus Medical (GMED), Irhythm Technologies (IRTC), Nevro (NVRO), Integra Lifesciences (IART), Haemonetics (HAE), ICU Medical (ICUI) and Inari Medical (NARI).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), NVIDIA (NVDA), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), salesforce.com (CRM) and Roku (ROKU).

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

Novocure's stock is owned by many different retail and institutional investors. Top institutional shareholders include Macquarie Group Ltd. (0.93%), Rhenman & Partners Asset Management AB (0.37%), Goldman Sachs Group Inc. (0.37%), C WorldWide Group Holding A S (0.34%), Hartline Investment Corp (0.33%) and Bank of New York Mellon Corp (0.29%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti.
View institutional ownership trends for Novocure.

NVCR stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Frontier Capital Management Co. LLC, Healthcare of Ontario Pension Plan Trust Fund, Nicholas Investment Partners LP, American International Group Inc., Bank of New York Mellon Corp, Goldman Sachs Group Inc., and First Trust Advisors LP. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, and William F Doyle.
View insider buying and selling activity for Novocure.

NVCR stock was purchased by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Kornitzer Capital Management Inc. KS, New York State Common Retirement Fund, State Board of Administration of Florida Retirement System, Bullseye Asset Management LLC, Peregrine Capital Management LLC, Swiss National Bank, and Phoenix Holdings Ltd..
View insider buying and selling activity for Novocure.

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVCR stock can currently be purchased for approximately $74.54.

Novocure has a market capitalization of $7.54 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

The official website for Novocure is www.novocure.com.

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]